TLP
VERA icon

Tri Locum Partners’s Vera Therapeutics VERA Stock Holding History

Tri Locum Partners’s Portfolio VERA Stock Details VERA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-805,689
Closed -$40.8M – 21
2025
Q4 		$40.8M Sell
805,689
-384,518
-32% -$13.7M 5.3% 10
2025
Q3 		$34.6M Buy
1,190,207
+777,093
+188% +$18M 7.95% 6
2025
Q2 		$9.73M Buy
413,114
+262,907
+175% +$5.91M 2.95% 13
2025
Q1 		$3.61M Buy
+150,207
New +$4.83M 1.85% 18
2023
Q4 		– Sell
-43,438
Closed -$596K – 58
2023
Q3 		$596K Sell
43,438
-65,490
-60% -$1.12M 0.19% 38
2023
Q2 		$1.75M Buy
+108,928
New +$984K 0.65% 32

Other funds holding VERA

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Tri Locum Partners's VERA Position: Q1 2026 in Review

Tri Locum Partners sold out of Vera Therapeutics (VERA) in Q1 2026, closing a stake of 805,689 shares — an estimated $40.8M sold.

Tri Locum Partners first reported a position in VERA in Q2 2023 and held it in 6 quarters. The position peaked at $40.8M in Q4 2025. 229 funds tracked by Wall St. Rank hold VERA as of Q1 2026.

  • Tri Locum Partners reported no remaining Vera Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Tri Locum Partners sold 805,689 Vera Therapeutics shares in Q1 2026, an estimated $40.8M.
  • Tri Locum Partners first reported a position in Vera Therapeutics in Q2 2023 and held it in 6 quarters.
  • Tri Locum Partners's Vera Therapeutics position peaked at $40.8M in Q4 2025.
  • 229 funds tracked by Wall St. Rank held Vera Therapeutics as of Q1 2026.

Based on Tri Locum Partners's 13F filing for Q1 2026, filed 18 May 2026.